A 44-year-old man with established MS presents with worsening spasticity, hyperreflexia, and a positive Babinski sign bilaterally. He reports progressive difficulty walking over the past 18 months without distinct relapses. Current imaging shows spinal cord atrophy with multiple T2 lesions. Which of the following medications is most appropriate to slow disease progression?
- A)FingolimodGABARITO
- B)Baclofen monotherapy
- C)Glatiramer acetate
- D)Interferon beta-1a
- E)Methylprednisolone
Explicação
This patient has secondary progressive MS (progression without relapses). Fingolimod, a sphingosine-1-phosphate receptor modulator, is FDA-approved for progressive MS and has demonstrated efficacy in slowing disability progression in both SPMS and PPMS populat... Ver explicação completa e trilha adaptativa →